Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (783)	2/5/2004 2:53:56 AM
From: Icebrg	Read Replies (2) \| Respond to of 2240

Genmab - 2003. From today's report. Highlights During 2003, Genmab had a large number of accomplishments including: HuMax-CD4 * Initiated two Phase II clinical trials to treat cutaneous T-cell lymphoma (CTCL). * Presented positive preliminary results of two ongoing Phase II CTCL studies at American Society of Hematology (ASH) meeting in December 2003. * Expanded Phase II CTCL trials to include more patients and higher doses. * Discontinued plans to develop HuMax-CD4 for the treatment of psoriasis. HuMax-IL15/Amgen Alliance * Amgen (NASDAQ: AMGN - news) exercised commercialisation option for HuMax-IL15 and IL-15 receptor programs earlier than expected and Genmab received USD 10 million milestone payment. * Amgen expanded agreement to include a new antibody on an additional disease target. * Achieved second Amgen milestone by delivering an antibody targeting the IL-15 receptor and received USD 500,000 milestone payment. * Amgen assumed responsibility for further development costs. HuMax-EGFr * HuMax-EGFr shown to induce regression of certain established tumors in animal disease models. * Initiated Phase I/II clinical trial to treat head and neck cancer. HuMax-CD20 * In both laboratory studies and animal disease models, HuMax-CD20 appeared to be more effective at killing tumour cells than rituximab, a leading antibody product currently on the market. * Presented HuMax-CD20 data demonstrating unique binding properties at ASH. * Filed US Investigational New Drug and UK Clinical Trial Application to initiate Phase I/II clinical trials to treat non-Hodgkin's lymphoma. HuMax-HepC * Expanded product pipeline with HuMax-HepC to treat Hepatitis C. Roche Alliance * Reached first and second milestones under Roche agreement by establishing proof of concept for two different human antibodies. ACE BioSciences Collaboration * Announced new fungal infection program with ACE BioSciences. Sanquin Collaboration * Established a collaboration with Sanquin Blood Supply Foundation with intent to improve treatment for hemophilia patients.

To: Icebrg who wrote (783)	11/15/2004 3:18:20 PM
From: nigel bates	Read Replies (2) \| Respond to of 2240

A bit old... Xerion's Xstream® Technology Identifies a Novel Target for Cancer Therapy Press Release Munich / Germany, June 1, 2004 Xerion Pharmaceuticals AG, a privately held company, today announced that Xerion scientists together with their collaborators at Tufts University School of Medicine and the National Cancer Institute have discovered an extracellular form of heat shock protein (hsp) 90 and its role in cancer invasion. The results of the study appear in the June issue of Nature Cell Biology (Volume 6, 2004). Invasion is a key step in tumor progression that eventually leads to metastases when a disseminated tumor cell penetrates through the extracellular matrix and establishes a secondary tumor site elsewhere. To date there are no effective and safe treatments against metastases due to the lack of reliable validated drug targets. Hsp90 recently has gained significant attention as an important target for cancer therapeutics and hsp90 inhibitors are currently in Phase I and II clinical trials. Since hsp90 is also a key protein for normal cell function, there is some concern about treatment-related toxicity, especially if hsp90 inhibitors are unable to distinguish normal and cancer cells. In the published article entitled "Functional Proteomic Screens Reveal an Essential Extracellular Role for Hsp90 in Cancer Cell Invasiveness", the researchers used functional screens on the extracellular membrane proteome of a highly invasive hu-man tumor cell line. The screens integrated the use of Xerion's Xstream technology - integrating antibody phage display, Fluorophore-Assisted Light Inactivation (FALI) and mass spectrometry. The screens identified the extracellular hsp90 associated with tumor cell invasion. The researchers demonstrated a direct physical and functional interaction between hsp90 and matrix metalloprotease (MMP) 2, a primary player in the tumor invasion process. This opens the possibility for developing antibodies against hsp90 for the treatment of cancer. "This work highlights the relevance of validating function at the protein level. Genetic approaches would have missed the discovery of the novel mechanism of hsp90 action", said Daniel Jay, Ph.D., Professor at Tufts University and senior author of the paper. "This study introduces a functional proteomic approach using Xstream technology to identify and validate disease-relevant proteins that nicely complements classical ge-netic screens", added Leodevico Ilag, Ph.D., Chief Technology Officer at Xerion Pharmaceuticals and a co-author of the article. "These studies suggest anti-hsp90 antibodies may offer therapeutic options to patients with refractory cancers."